Vertex Pharmaceuticals Inc. shares surged to an all-time high of $555.84, pushing the company's market capitalization to $139.72 billion, as multiple Wall Street firms upgraded their outlooks following a competitor's unsuccessful cystic fibrosis trial.
Real-time data showed VRTX trading at $555.17, up $7.52 or 1.37%, as the stock moved just below its 52-week peak of $555.69. The shares have climbed roughly 40% over the past year, though InvestingPro analysis flagged the stock as trading above its fair-value estimate.
The rally was fueled by a spate of analyst notes reaffirming bullish ratings on the cystic fibrosis franchise. RBC Capital reiterated an Outperform rating with a $570 price target, while BMO Capital also repeated Outperform with a higher $600 target, both citing the impact of a rival drug candidate's failed trial. Bernstein SocGen Group named Vertex a top pick, assigning an Outperform rating and a $608 target, citing potential beyond the company's core cystic fibrosis business. Wolfe Research raised its price target to $562 from $557, highlighting the strength of the Trikafta franchise. Bank of America added the stock to its US 1 List as a top investment idea.
Vertex's cystic fibrosis franchise, anchored by Trikafta, remains the primary driver of investor enthusiasm. With one competitor's clinical setback clearing the field further, analysts see limited near-term risk to Vertex's dominant position in the treatment landscape for cystic fibrosis patients.
The stock's momentum has outpaced many peers in the pharma sector, though the above-fair-value reading from InvestingPro suggests some investors may be pricing in more optimism than the fundamental metrics alone support. The company's market cap now approaches $140 billion, placing it firmly among the largest U.S. biotech and pharmaceutical names by valuation.
